Ivacaftor/lumacaftor changes the lung microbiome and metabolome in cystic fibrosis patients

A. Neerincx (Amsterdam, Netherlands), K. Whiteson (Irvine, California, United States of America), J. Phan (Irvine, California, United States of America), P. Brinkman (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), J. Altenburg (Amsterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands)

Source: Virtual Congress 2020 – Advances in cystic fibrosis: from microbiome to MRI
Session: Advances in cystic fibrosis: from microbiome to MRI
Session type: Oral Presentation
Number: 4337
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Neerincx (Amsterdam, Netherlands), K. Whiteson (Irvine, California, United States of America), J. Phan (Irvine, California, United States of America), P. Brinkman (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), J. Altenburg (Amsterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands). Ivacaftor/lumacaftor changes the lung microbiome and metabolome in cystic fibrosis patients. 4337

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics
Source: Eur Respir J 2014; 44: 922-930
Year: 2014



The microbiome in interstitial lung disease
Source: Lung Science Conference 2015
Year: 2015




Bacterial infection and lung function in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 615s
Year: 2005

The cystic fibrosis lower airways microbial metagenome
Source: ERJ Open Res 2016: 00096-2015
Year: 2016



The lung microbiome in chronic suppurative lung disease: cystic fibrosis and non-cystic fibrosis bronchiectasis
Source: Eur Respir Monogr 2019; 83: 158-172
Year: 2019


Longitudinal changes in lung function and the association with pulmonary structure and infection in infants with cystic fibrosis
Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Year: 2008

Molecular detection of complex microbial communities in sputa of patients with cystic fibrosis and non cystic fibrosis bronchiectasis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010

Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease
Source: Eur Respir J 2002; 20: Suppl. 38, 528s
Year: 2002

The pulmonary microbiome in non-cystic fibrosis bronchiectasis.
Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Year: 2017

Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis, non-specific interstitial pneumonia and human donor lungs
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008

A molecular comparison of microbial communities in bronchiectasis and cystic fibrosis
Source: Eur Respir J 2013; 41: 991-993
Year: 2013


Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens
Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019
Year: 2019



Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis
Source: Eur Respir J 2016; 48: 1612-1621
Year: 2016



Comparison of progression in lung structure and lung function in children and adolescents with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 714s
Year: 2006

Improving airway clearance in cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 169-187
Year: 2014


Genotype and progressive lung damage in adult cystic fibrosis patients
Source: Eur Respir J 2003; 22: Suppl. 45, 502s
Year: 2003

The pulmonary microbiome in sarcoidosis is similar to other parenchymal lung diseases
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018



Microcirculation alterations in adult patients with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 262s
Year: 2006

Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
Source: Eur Respir J, 52 (3) 1702529; 10.1183/13993003.02529-2017
Year: 2018



Relations between the sinonasal development and the lung disease in cystic fibrosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 103s
Year: 2005